Week in Review: WuXi Healthcare Ventures II Files for $250 Million Fund

WuXi Healthcare Ventures Fund II filed US paperwork for a $250 million life sciences venture fund with WuXi AppTec on record as contributing up to $50 million as an anchor investor; Zhongzhi Pharma of Guangdong raised $73 million in a Hong Kong IPO; Phoenix Healthcare, a Beijing hospital company, paid $23.2 million for a 20% stake in clinic operator UMP Healthcare; Frontage Labs, a US-China CRO, acquired a biostatistics firm, BDM Consulting; CANbridge Life Sciences of Beijing in-licensed China rights to brain cancer drug candidate from Apogenix of Germany; Hengrui Medicine announced plans to spend $137 million building a biologic drug manufacturing facility in Suzhou; Aoxing Pharma reported positive results from a China trial of an opioid dependence therapy; a gastric cancer screening test developed by Finland's Biohit Oyj will be studied in 20,000 China patients; and the Minister of the CFDA warned that focusing on the cost of generic drugs will cause problems in quality. More details.... Stock Symbols: (NYSE: WX) (HK: 3737) (HK: 1515) (SHA: 600276) (HEL: BIOBV) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.